{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-046536","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2026-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.629653+00:00","generated_at":"2026-05-16T03:18:39.257430+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vikings Q4 net loss $157.7M; cash $706M; oral VK2735 Phase 3 to start 3Q26","bullets":["Full-year 2025 net loss $358.5M ($3.19/sh) vs $110.0M in 2024; R&D spend $345M (up 240% YoY).","Cash & investments $706M at Dec 31, 2025 vs $903M a year earlier; burn reflects Phase 3 ramp.","VANQUISH-1 (obesity) enrollment completed >4,500 ahead of schedule; VANQUISH-2 (obesity+diabetes) near full.","Oral VK2735 to advance to Phase 3 in 3Q26 after FDA end-of-Phase 2 meeting; maintenance dosing data due 3Q26.","IND filing for novel amylin agonist planned in 1Q26; Phase 1 maintenance study fully enrolled."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-046536","json":"https://secwatch.observer/filing/0001193125-26-046536.json","markdown":"https://secwatch.observer/filing/0001193125-26-046536.md","text":"https://secwatch.observer/filing/0001193125-26-046536.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526046536/0001193125-26-046536-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526046536/vktx-20260211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:18:39.257430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}